Transgene S.A. Stock
Price
Target price
€1.84
€1.84
-0.430%
-0.008
-0.430%
-
29.03.23 / Frankfurt
WKN: 913048 / Symbol: TRGNF / Name: Transgene / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Transgene S.A. Stock
Transgene S.A. shows a slight decrease today, losing -€0.008 (-0.430%) compared to yesterday.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Transgene S.A. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Transgene S.A. in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Transgene S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Transgene S.A. | -0.430% | 1.314% | -6.377% | -19.037% | 11.985% | 54.167% | -36.968% |
| Erytech Pharma S.A. | -5.110% | 18.123% | 5.632% | -42.274% | 153.308% | - | - |
| Nanobiotix | -2.260% | 3.750% | -2.639% | -48.287% | -6.347% | -39.361% | -73.776% |
| Avadel Pharmaceuticals plc ADR | -1.760% | 3.125% | -12.698% | - | 27.907% | - | - |
Comments
News
Transgene Announces Upcoming Investor Meetings
Regulatory News:
TRANSGENE (Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that Management will participate in
Transgene: 2022 Full-year Results and Business Update
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial
Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will be presenting eight posters
